An official website of the United States government
Home
Name
Xpovio
Alternate Names
selinexor
Abbreviations
None
Category
Chemotherapy
Subcategory
CRM1 Inhibitor
NSC Number
None
Primary Site
None
Histology
Multiple myeloma; DLBCL
Remarks
12/18/2020 The FDA approved selinexor (XPOVIO) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
6/22/2020 The FDA granted accelerated approval to selinexor (XPOVIO) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy
July 3, 2019.FDA granted accelerated approval to selinexor (XPOVIO) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
6/22/2020 The FDA granted accelerated approval to selinexor (XPOVIO) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy
July 3, 2019.FDA granted accelerated approval to selinexor (XPOVIO) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
Coding
This drug should be coded
